ResearcherShanghai Jiao Tong UniversityActive in the last 2 years
Yong-Wei Sun
Matched on OpenAlex author ID A5103571811. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 15
2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper · 2025: none · 2026: 2 papers
Papers 4
- Retraction: Overexpressed EDIL3 predicts poor prognosis and promotes anchorage-independent tumor growth in human pancreatic cancer. Last author DOI 10.18632/oncotarget.28909↗
- L-Lactate reprograms tumor-associated macrophages to drive pancreatic cancer progression via BCL3 lactylation Last author DOI 10.64898/2026.03.06.710237↗
- Evaluation of a new scoring system for assessing nerve invasion in resected pancreatic cancer: A single-center retrospective analysis. Co-author DOI 10.1016/j.canlet.2024.217213↗
- Influence of perineural invasion on survival and recurrence in patients with resected pancreatic cancer. Co-author DOI 10.7314/apjcp.2013.14.9.5133↗
Closest collaborators
The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Minwei Yang · 3 shared papers, 2024–2026 · strength 0.64
- Paper L-Lactate reprograms tumor-associated macrophages to drive pancreatic cancer progression via BCL3 lactylation DOI 10.64898/2026.03.06.710237↗
- Paper Retraction: Overexpressed EDIL3 predicts poor prognosis and promotes anchorage-independent tumor growth in human pancre… DOI 10.18632/oncotarget.28909↗
- Paper Evaluation of a new scoring system for assessing nerve invasion in resected pancreatic cancer: A single-center retrospe… DOI 10.1016/j.canlet.2024.217213↗
- Jian‐Yu Yang · 2 shared papers, 2026 · strength 0.46
- Paper L-Lactate reprograms tumor-associated macrophages to drive pancreatic cancer progression via BCL3 lactylation DOI 10.64898/2026.03.06.710237↗
- Paper Retraction: Overexpressed EDIL3 predicts poor prognosis and promotes anchorage-independent tumor growth in human pancre… DOI 10.18632/oncotarget.28909↗
- Xueliang Fu · 2 shared papers, 2026 · strength 0.46
- Paper L-Lactate reprograms tumor-associated macrophages to drive pancreatic cancer progression via BCL3 lactylation DOI 10.64898/2026.03.06.710237↗
- Paper Retraction: Overexpressed EDIL3 predicts poor prognosis and promotes anchorage-independent tumor growth in human pancre… DOI 10.18632/oncotarget.28909↗
- Shu‐Heng Jiang · 2 shared papers, 2026 · strength 0.46
- Paper L-Lactate reprograms tumor-associated macrophages to drive pancreatic cancer progression via BCL3 lactylation DOI 10.64898/2026.03.06.710237↗
- Paper Retraction: Overexpressed EDIL3 predicts poor prognosis and promotes anchorage-independent tumor growth in human pancre… DOI 10.18632/oncotarget.28909↗
- Rong Hua · 2 shared papers, 2024–2026 · strength 0.41
- Paper Retraction: Overexpressed EDIL3 predicts poor prognosis and promotes anchorage-independent tumor growth in human pancre… DOI 10.18632/oncotarget.28909↗
- Paper Evaluation of a new scoring system for assessing nerve invasion in resected pancreatic cancer: A single-center retrospe… DOI 10.1016/j.canlet.2024.217213↗
- Pei‐Xuan Ji · 1 shared paper, 2026 · strength 0.24
- Jia-Hao Zheng · 1 shared paper, 2026 · strength 0.24
- Jun-Feng Zhang · 2 shared papers, 2013–2024 · strength 0.23
- Paper Evaluation of a new scoring system for assessing nerve invasion in resected pancreatic cancer: A single-center retrospe… DOI 10.1016/j.canlet.2024.217213↗
- Paper Influence of perineural invasion on survival and recurrence in patients with resected pancreatic cancer. DOI 10.7314/apjcp.2013.14.9.5133↗
- Zhigang Zhang · 1 shared paper, 2026 · strength 0.22
- Shan Zhang · 1 shared paper, 2024 · strength 0.19
- Hong‐Fei Yao · 1 shared paper, 2024 · strength 0.19
- Wei Liu · 1 shared paper, 2024 · strength 0.19
- Jiao Li · 1 shared paper, 2013 · strength 0.04
- Rong Hua · 1 shared paper, 2013 · strength 0.04
- Wei Chiang Liu · 1 shared paper, 2013 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.